dc.creator | Salvadó G,Antonio | |
dc.creator | Ramolfo B,Pamela | |
dc.creator | Escobar M,Marisol | |
dc.creator | Núñez C,Alejandra | |
dc.creator | Aguayo T,Inés | |
dc.creator | Standen H,Jane | |
dc.creator | Sánchez G,Lina | |
dc.creator | Cabello M,Angela | |
dc.date | 2000-12-01 | |
dc.date.accessioned | 2019-09-10T12:39:39Z | |
dc.date.available | 2019-09-10T12:39:39Z | |
dc.identifier | https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872000001200002 | |
dc.identifier.uri | https://revistaschilenas.uchile.cl/handle/2250/105333 | |
dc.description | Background: Anemia is common among very low birth weight newborns and requires frequent blood tranfusions. Erythropoietin was been reported to be useful in the prevention of this anemia. Aim: To asses the benefits of early (before the third week of life) Human recombinant Erythropoietin (r-EPO) administration to reduce the requirement of blood tranfusions in very low birth weight newborns. Patients and methods: sixty newborns under 1500g of birthweight were randomly assigned to recive r-EPO (n=29) or placebo (n=31) three times per week, during four weeks. Packed red cell volume and reticulocyte counts were measured weekly. Serum erythropoietin was measured prior to eigth dose. Transfusion requirements were recorded. Results: r-EPO reduced transfusions from 1.41 ± 1.1 to 0.69 ± 1 transfusions/newborns (p<0.001). At the fourth week of treatment, reticulocyte count was 14.8 ± 7 and 6.4 ± 4.9% in the active treatment group and placebo group respectively (p<0.001). Conclusions: r-EPO reduces the requrement of transfusions in low birth weight infants (Rev Méd Chile 2000; 128: 1313-17). | |
dc.format | text/html | |
dc.language | es | |
dc.publisher | Sociedad Médica de Santiago | |
dc.relation | 10.4067/S0034-98872000001200002 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.source | Revista médica de Chile v.128 n.12 2000 | |
dc.subject | Anemia neonatal | |
dc.subject | Erythropoietin | |
dc.subject | Infant, low birth weight | |
dc.title | Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro | |